SecBot SecBot
6-K ·Filed Sep 4, 2026

NVS

NOVARTIS AG
BEARISH
Impact 6/10
Horizonimmediate Processed2mo ago SEC0001171843-26-005896
Notable filing: 6-K
Actionable Insight ▼ Bearish

Expect a negative stock reaction as the market prices in the loss of a major pipeline asset. Monitor for analyst downgrades of Novartis's net present value (NPV) for pelacarsen and any potential write-downs related to the Ionis license. The full data presentation at an upcoming medical congress may provide further detail on subgroup analyses.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$137.70
T+0 close · Sep 4, 2026 · via day close
Latest settled
+2.24%
T+20 · $140.79 · next T+60 in 16d
Vs SPY
+0.53%
α at T+20
Latest observation
+19.78%
T+48 · FF3 residual α
  1. T+0 · Sep 8 $137.70entry
  2. T+1 · 2mo ago −0.16%α +0.30% · $137.48
  3. T+5 · 2mo ago +0.67%α +1.79% · $138.62
  4. T+20 · 6w ago +2.24%α +0.53% · $140.79
  5. T+49 · todayOpen
  6. T+60 · in 16d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Novartis announced that its Phase III Lp(a)HORIZON trial for pelacarsen, an investigational antisense oligonucleotide targeting elevated lipoprotein(a), did not meet the primary endpoint of reducing cardiovascular events in patients with elevated Lp(a) and established CVD. Despite achieving lower Lp(a) levels, the drug failed to translate biomarker reduction into clinical benefit, eliminating a major pipeline opportunity in a large unmet cardiovascular market.

Key Facts

  • Pelacarsen Phase III Lp(a)HORIZON trial (NCT04023552) did not meet its primary composite endpoint of cardiovascular death, non-fatal MI, non-fatal stroke, and urgent coronary revascularization requiring hospitalization.
  • Trial enrolled 8,323 patients with elevated Lp(a) (≥70 mg/dL) and established CVD; lower Lp(a) levels were achieved but did not reduce cardiovascular risk.
  • Novartis obtained global rights to pelacarsen under a license and collaboration agreement with Ionis Pharmaceuticals.
  • Elevated Lp(a) affects approximately 20% of the global population with no approved targeted treatment.

Financial Impact

Failure of a high-profile Phase III cardiovascular outcomes trial eliminates a significant future revenue opportunity for Novartis; no specific financial figures provided in the filing.

revenuepipeline value

Risk Factors

  • Potential impairment of intangible assets related to the pelacarsen license from Ionis Pharmaceuticals.
  • Loss of future revenue stream from a drug targeting a large unmet cardiovascular need.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
47% bullish (34 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-005896
Document: 0001171843-26-005896-index-headers.html0001171843-26-005896
Document: 0001171843-26-005896-index.html0001171843-26-005896
Document: 0001171843-26-005896.txt0001171843-26-005896

Track record

16 reports on NVS

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +6.86% at T+60 after the Jul 1, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 12, 20263d ago 6-K Neutral 3/10 Entry $160.98 Now $160.20 −0.48% due Nov 16
  2. Nov 10, 20266d ago PTAB Trial Neutral 3/10 Entry $163.26 to $160.32 Now $160.20 −1.87% ▼ −1.80% −3.12% vs SPY
  3. Oct 28, 202619d ago 144 Neutral 2/10 Entry $156.08 to $161.10 Now $160.20 +2.64% ▲ +3.22% +3.60% vs SPY
  4. Oct 27, 202620d ago 6-K Mixed 6/10 Entry $156.86 to $156.08 Now $160.20 +2.13% ▼ −0.50% −0.84% vs SPY
  5. Oct 15, 20264w ago Court Ruling Neutral 2/10 Entry $150.62 to $150.20 Now $160.20 +6.36% ▼ −0.28% −0.70% vs SPY
  6. Oct 13, 20264w ago Court Ruling Bearish 5/10 Entry $146.88 to $150.38 Now $160.20 −9.07% ▼ −2.38% −2.10% vs SPY
  7. Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $141.28 to $142.71 Now $160.20 +13.39% ▲ +1.01% +1.73% vs SPY
  8. Sep 4, 202610w ago 6-K Bearish 6/10 Viewing Entry $137.70 to $137.48 Now $160.20 −16.34% ▲ +0.16% −0.30% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $161.25 to $162.46 Now $160.20 −0.65% ▲ +0.75% +0.31% vs SPY
  10. Aug 4, 202614w ago Court Ruling Neutral 2/10 Entry $154.44 to $154.21 Now $160.20 +3.73% ▼ −0.15% +0.01% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Tue (17h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 4, 2026